Continuous Arterial Spin Labeling (CASL) MRI for Monitoring and Prediction of Drug Therapy in Alzheimers Disease (AD)

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Examination of the correlation between the cerebral bloodflow and the clinical change under treatment with Reminyl retard® and the prediction of clinical change by measuring the cerebral bloodflow in patients with mild to moderate Alzheimer's Disease

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Bonn
• Collaborator: Federal Ministry of Health, Germany
• Treatments: Galantamine

Criteria

Inclusion Criteria:

• Possible Alzheimer's Disease according to ICD-10 and NINCDS-ADRDA

• Underwritten study consent

• No treatment with acetylcholinesterase inhibitors

• Mini-Mental-State Examination: 12-25 points

• Age: 50-80 Years

• Orale contraception for women of child-bearing age

Exclusion Criteria:

• Mental Disorders

• Other Diseases of the CNS

• Severe Illness

• Contraindication for MRI-Scan

• Contraindication for Galantamin (Reminyl retard®)

• Participation at other clinical trials